Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues

Ingrid E. Wertz, Arline D. Deitch, Paul H. Gumerlock, Regina Gandour-Edwards, Sung-Gil Chi, Ralph W. De Vere White

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The prognostic value of the p53 gene (TP53), the most commonly mutated gene in human cancers, has been well established for several cancer types. However, because varying frequencies of TP53 mutations have been identified in prostatic adenocarcinoma (CaP) by genetic and immunohistochemical (IHC) studies, the role of TP53 in CaP tumorigenesis is currently unresolved. These experimental discrepancies could be caused by tissue heterogeneity within prostatic neoplasms, variations in experimental protocols, or other factors. Thus, the goal of this study was to develop a reliable IHC approach for the detection of p53 in archival prostate tissue. The authors evaluated four p53 antibodies, CM-1, 1801, DO-1, and DO-7, for their ability to reveal p53. They chose two reference CaP cell lines, 26 patient specimens (including eight benign prostatic hyperplasias (BPHs), 16 CaPs, and two lymph node metastases), one prostate and nine kidney cell lines for p53 analysis. The TP53 status of these samples was characterized using single-strand conformational polymorphism (SSCP) analysis of RNA/PCR products and sequencing. IHC detection of p53 was markedly enhanced by using the combination of microwave heat-induced antigen unto g anti a cocktail of the DO-1 and DO-7 antibodies. This approach identified 14 of 15 (93%) cell lines and patient samples having TP53 missense mutations in the exons 5 to 8 region. Of the 21 patient samples and cell lines that were either normal by SSCP or expressed p53 mutations that are not expected to stain, 18 (86%) were immunonegative. Because of this good correlation between molecular and IHC analysis, this approach may help to resolve the uncertainty about TP53 in CaP tumorigenesis.

Original languageEnglish
Pages (from-to)573-580
Number of pages8
JournalHuman Pathology
Volume27
Issue number6
DOIs
Publication statusPublished - 1996 Jun 27

Fingerprint

Prostate
Cell Line
Mutation
Carcinogenesis
Antibodies
p53 Genes
Prostatic Hyperplasia
Mutation Rate
Missense Mutation
Microwaves
Uncertainty
Exons
Neoplasms
Prostatic Neoplasms
Adenocarcinoma
Coloring Agents
Hot Temperature
Lymph Nodes
RNA
Neoplasm Metastasis

Keywords

  • antigen unmasking
  • immunohistochemistry
  • p53
  • prostatic neoplasms
  • single strand conformational polymorphism
  • TP53

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Wertz, I. E., Deitch, A. D., Gumerlock, P. H., Gandour-Edwards, R., Chi, S-G., & De Vere White, R. W. (1996). Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Human Pathology, 27(6), 573-580. https://doi.org/10.1016/S0046-8177(96)90164-1

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. / Wertz, Ingrid E.; Deitch, Arline D.; Gumerlock, Paul H.; Gandour-Edwards, Regina; Chi, Sung-Gil; De Vere White, Ralph W.

In: Human Pathology, Vol. 27, No. 6, 27.06.1996, p. 573-580.

Research output: Contribution to journalArticle

Wertz, IE, Deitch, AD, Gumerlock, PH, Gandour-Edwards, R, Chi, S-G & De Vere White, RW 1996, 'Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues', Human Pathology, vol. 27, no. 6, pp. 573-580. https://doi.org/10.1016/S0046-8177(96)90164-1
Wertz, Ingrid E. ; Deitch, Arline D. ; Gumerlock, Paul H. ; Gandour-Edwards, Regina ; Chi, Sung-Gil ; De Vere White, Ralph W. / Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. In: Human Pathology. 1996 ; Vol. 27, No. 6. pp. 573-580.
@article{4e466f406607468a95184a62f4353d5f,
title = "Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues",
abstract = "The prognostic value of the p53 gene (TP53), the most commonly mutated gene in human cancers, has been well established for several cancer types. However, because varying frequencies of TP53 mutations have been identified in prostatic adenocarcinoma (CaP) by genetic and immunohistochemical (IHC) studies, the role of TP53 in CaP tumorigenesis is currently unresolved. These experimental discrepancies could be caused by tissue heterogeneity within prostatic neoplasms, variations in experimental protocols, or other factors. Thus, the goal of this study was to develop a reliable IHC approach for the detection of p53 in archival prostate tissue. The authors evaluated four p53 antibodies, CM-1, 1801, DO-1, and DO-7, for their ability to reveal p53. They chose two reference CaP cell lines, 26 patient specimens (including eight benign prostatic hyperplasias (BPHs), 16 CaPs, and two lymph node metastases), one prostate and nine kidney cell lines for p53 analysis. The TP53 status of these samples was characterized using single-strand conformational polymorphism (SSCP) analysis of RNA/PCR products and sequencing. IHC detection of p53 was markedly enhanced by using the combination of microwave heat-induced antigen unto g anti a cocktail of the DO-1 and DO-7 antibodies. This approach identified 14 of 15 (93{\%}) cell lines and patient samples having TP53 missense mutations in the exons 5 to 8 region. Of the 21 patient samples and cell lines that were either normal by SSCP or expressed p53 mutations that are not expected to stain, 18 (86{\%}) were immunonegative. Because of this good correlation between molecular and IHC analysis, this approach may help to resolve the uncertainty about TP53 in CaP tumorigenesis.",
keywords = "antigen unmasking, immunohistochemistry, p53, prostatic neoplasms, single strand conformational polymorphism, TP53",
author = "Wertz, {Ingrid E.} and Deitch, {Arline D.} and Gumerlock, {Paul H.} and Regina Gandour-Edwards and Sung-Gil Chi and {De Vere White}, {Ralph W.}",
year = "1996",
month = "6",
day = "27",
doi = "10.1016/S0046-8177(96)90164-1",
language = "English",
volume = "27",
pages = "573--580",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues

AU - Wertz, Ingrid E.

AU - Deitch, Arline D.

AU - Gumerlock, Paul H.

AU - Gandour-Edwards, Regina

AU - Chi, Sung-Gil

AU - De Vere White, Ralph W.

PY - 1996/6/27

Y1 - 1996/6/27

N2 - The prognostic value of the p53 gene (TP53), the most commonly mutated gene in human cancers, has been well established for several cancer types. However, because varying frequencies of TP53 mutations have been identified in prostatic adenocarcinoma (CaP) by genetic and immunohistochemical (IHC) studies, the role of TP53 in CaP tumorigenesis is currently unresolved. These experimental discrepancies could be caused by tissue heterogeneity within prostatic neoplasms, variations in experimental protocols, or other factors. Thus, the goal of this study was to develop a reliable IHC approach for the detection of p53 in archival prostate tissue. The authors evaluated four p53 antibodies, CM-1, 1801, DO-1, and DO-7, for their ability to reveal p53. They chose two reference CaP cell lines, 26 patient specimens (including eight benign prostatic hyperplasias (BPHs), 16 CaPs, and two lymph node metastases), one prostate and nine kidney cell lines for p53 analysis. The TP53 status of these samples was characterized using single-strand conformational polymorphism (SSCP) analysis of RNA/PCR products and sequencing. IHC detection of p53 was markedly enhanced by using the combination of microwave heat-induced antigen unto g anti a cocktail of the DO-1 and DO-7 antibodies. This approach identified 14 of 15 (93%) cell lines and patient samples having TP53 missense mutations in the exons 5 to 8 region. Of the 21 patient samples and cell lines that were either normal by SSCP or expressed p53 mutations that are not expected to stain, 18 (86%) were immunonegative. Because of this good correlation between molecular and IHC analysis, this approach may help to resolve the uncertainty about TP53 in CaP tumorigenesis.

AB - The prognostic value of the p53 gene (TP53), the most commonly mutated gene in human cancers, has been well established for several cancer types. However, because varying frequencies of TP53 mutations have been identified in prostatic adenocarcinoma (CaP) by genetic and immunohistochemical (IHC) studies, the role of TP53 in CaP tumorigenesis is currently unresolved. These experimental discrepancies could be caused by tissue heterogeneity within prostatic neoplasms, variations in experimental protocols, or other factors. Thus, the goal of this study was to develop a reliable IHC approach for the detection of p53 in archival prostate tissue. The authors evaluated four p53 antibodies, CM-1, 1801, DO-1, and DO-7, for their ability to reveal p53. They chose two reference CaP cell lines, 26 patient specimens (including eight benign prostatic hyperplasias (BPHs), 16 CaPs, and two lymph node metastases), one prostate and nine kidney cell lines for p53 analysis. The TP53 status of these samples was characterized using single-strand conformational polymorphism (SSCP) analysis of RNA/PCR products and sequencing. IHC detection of p53 was markedly enhanced by using the combination of microwave heat-induced antigen unto g anti a cocktail of the DO-1 and DO-7 antibodies. This approach identified 14 of 15 (93%) cell lines and patient samples having TP53 missense mutations in the exons 5 to 8 region. Of the 21 patient samples and cell lines that were either normal by SSCP or expressed p53 mutations that are not expected to stain, 18 (86%) were immunonegative. Because of this good correlation between molecular and IHC analysis, this approach may help to resolve the uncertainty about TP53 in CaP tumorigenesis.

KW - antigen unmasking

KW - immunohistochemistry

KW - p53

KW - prostatic neoplasms

KW - single strand conformational polymorphism

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=0029948503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029948503&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(96)90164-1

DO - 10.1016/S0046-8177(96)90164-1

M3 - Article

VL - 27

SP - 573

EP - 580

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -